<DOC>
	<DOCNO>NCT00809757</DOCNO>
	<brief_summary>A Safety , Efficacy , Tolerability Study Daily Dosing Levalbuterol Tartrate HFA MDI Placebo Subjects Aged Birth &lt; 48 Months Asthma .</brief_summary>
	<brief_title>A Safety , Efficacy Tolerability Study Pediatric Subjects With Asthma</brief_title>
	<detailed_description>This modified-blind , randomize , placebo-controlled , multicenter , parallel-group trial levalbuterol HFA MDI administer use facemask hold chamber subject birth &lt; 48 month asthma . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Subject 's parent/legal guardian must give write informed consent , include privacy authorization , prior study participation . Complete documentation regard consent process must record case report form ( CRF ) source documentation . Subject 's parent/legal guardian must willing able comply study procedure visit schedule . Subject , male female , must age birth &lt; 48 month , exclusive , time consent . Subjects 24 &lt; 48 month age must history physiciandiagnosed asthma ( define least 3 episode respiratory symptom consistent asthma symptom include , limited , cough , wheeze , dyspnea ) . Subjects 0 &lt; 24 month age must history 3 episode respiratory symptom judgement investigator could consistent asthma reactive airway disease . Subject must good health affect chronic condition , include respiratory disorder asthma . In subject chest radiograph ( take 12 month prior screen visit ) , evidence chronic cardiopulmonary condition asthma present discern Investigator . Subject 's parent/legal guardian must able complete diary card medical event calendar ( MEC ) reliably daily basis understand dose instruction questionnaire completion . Subject require expect require disallow medication Subject participate investigational drug study within 30 day prior screen , currently participate another clinical trial . Subject parent/legal guardian daily commitment study would interfere trial measurement , compliance , . Subject history hospitalization asthma , reactive airway disease , bronchospasm within 4 week prior screen schedule inpatient hospitalization , include elective surgery course trial . Subject experience significant blood loss within 60 day study drug . Subject clinical diagnosis cystic fibrosis . Subject born prematurely , define less 38 week gestational age birth , &lt; 1 year age screening Subject whose body weight less 7.0 kg screening . This minimum weight requirement base upon standard pediatric growth chart [ CDC 2000 ] . Subject known sensitivity levalbuterol racemic albuterol , excipients contain formulation . Subject use prescription drug levalbuterol racemic albuterol sulfate administration contraindicate . Subject history lifethreatening asthma , define previous asthma episode require intubation associate hypercapnia , respiratory arrest , hypoxic seizure . Subject clinically significant abnormality may interfere metabolism excretion study drug study participation ( eg , abnormality renal , hepatic , metabolic , endocrine function ) . Subject history cancer . Subject chronic congenital cardiorespiratory condition asthma include , limited , bronchopulmonary dysplasia , congenital heart disease , cystic fibrosis . Subject affect upper low respiratory tract infection 3 week prior screen . Subject history ventilation respiratory condition occur near birth , include associate prematurity bronchopulmonary dysplasia . Ventilatory support elective noncardiopulmonary surgery exclusionary . Subject clinically significant abnormal laboratory value ( hematology , blood chemistry ) . Subject clinically significant abnormal 12lead ECG would put subject risk experience adverse cardiac effect . Subject relative staff member .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Asthma</keyword>
</DOC>